Redefining Long Term Success in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

In this segment, the discussion returns to the theme of long term management in EGFR mutated metastatic non-small cell lung cancer. Dr. Rous reflects on how alternative administration strategies, including subcutaneous delivery and less frequent dosing schedules, may reduce time toxicity and improve the overall treatment experience. She emphasizes that as patients remain on therapy for extended periods, convenience, visit frequency, and logistical burden become increasingly important determinants of adherence.

The panel then broadens the conversation to define what treatment success means beyond traditional endpoints such as progression free survival and overall survival. Panelists highlight the importance of maintaining functional independence, preserving quality of life, minimizing toxicity, and enabling patients to continue meaningful daily activities. The discussion underscores that durable disease control must be paired with sustainable tolerability. This segment reframes success in EGFR mutated metastatic non-small cell lung cancer as a balance between clinical efficacy and patient centered outcomes.